September 26, 2011
AstraZeneca Pharmaceuticals LP on Monday agreed to pay $20 million to settle claims brought in Delaware by a putative class of direct purchasers of Toprol-XL who allege the pharmaceutical giant used sham patent litigation to delay generic competition for the hypertension drug.